Porphyria cutanea tarda in association with the human immunodeficiency virus infection. NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Porphyria cutanea tarda in association with the human immunodeficiency virus infection.

Postgrad Med J. 1988 Dec;64(758):956-7. Unique Identifier : AIDSLINE MED/89386369
Ong EL; Ellis ME; McDowell D; Gebril M; Weinkove C; Ead R; Regional Department of Infectious Diseases and Tropical Medicine,; Monsall Hospital, Manchester, UK.

Abstract: A 42 year old heterosexual male with symptomatic human immunodeficiency virus infection presented with a 2-week history of tense blistering skin lesions following azidothymidine therapy. Urinary porphyrin excretion confirmed the diagnosis of porphyria cutanea tarda. The blisters resolved following the withdrawal of the drug but recurred when rechallenged. Three other cases of porphyria cutanea tarda, not associated with azidothymidine, who subsequently developed acquired immunodeficiency syndrome have recently been described. If azidothymidine is not the precipitating agent, it is possible that human immunodeficiency virus itself can impair porphyrin metabolism, leading to the clinical and biochemical features of porphyria cutanea tarda.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS/DRUG THERAPY Adult Case Report Human Male Porphyria/CHEMICALLY INDUCED/*COMPLICATIONS Skin Diseases/CHEMICALLY INDUCED/*COMPLICATIONS Zidovudine/ADVERSE EFFECTS JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/KWDcomplications/drugtherapyadultcasereporthumanmaleporphyria/chemicallyinduced/KWDcomplicationsskindiseases/chemicallyinduced/KWDcomplicationszidovudine/adverseeffectsjournalarticle
891230
M89C0768

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .